Fontan Global Case Conference Richard J. Czosek, MD 6/28/17 The Role of Catheter Ablation in Fontan Arrhythmia Control: Patient Based Decision Making Fontan Global Case Conference Richard J. Czosek, MD 6/28/17
Patient 1 20 yo with non-fenestrated extra-cardiac Fontan who recently had their first episode of atrial tachycardia They were cardioverted without issue and are now on Coumadin Currently 3 months from this first episode of tachycardia currently on no anti-arrhythmic medications Patient 2 43 yo with a atrio-pulmonary Fontan with history of multiple cardioversions for atrial tachycardia with recent increase in symptomatology and 3-4 episodes in the past 12 months History previous ablation procedure 4 years prior Currently on Coumadin as well as amiodarone with continued breakthrough episodes of tachycardia
Prevalence of Atrial Flutter/IART in Fontan 1973 - 1991 Fishberger, et al., Jour. Thor. Card. Surgery, 1997
Role of Trans-catheter Ablation Medication DCCV Surgical Ablation Pacing Rate Control
Recurrence of Atrial Tachycardia Egbe et al., Int. Journ. Of Cardiology, 2016
Risk of Atrial Tachycardia Recurrence Egbe et al, American Heart Journal, 2017
To ablate or not to ablate Don’t Ablate
When to ablate? Ablation DCCV/ Pacing Fontan + Arrhythmia Medications/ Rate Control
Fontan Patient Decision Tools Trans-catheter Ablation Medications Surgical Ablation Medications Trans-catheter Ablation Surgical Ablation Decision Fontan Patient Atrial Arrhythmia Surgical Ablation Medications Decision Tools Patient Age Fontan Type Tachycardia Type Frequency of Tachycardia Patient Risk Factors Rate of Tachycardia Patient Preference Physician Preference Center philosophy Monitor for Recurrence Medications Trans-catheter Ablation
Trans-catheter Ablation Patient Decision Tools Fontan Type Tachycardia Type Frequency of Tachycardia Patient Risk Factors Rate of Tachycardia Patient Preference Physician Preference Center philosophy Patient Age
Trans-catheter Ablation Patient Decision Tools Fontan Type Tachycardia Type Frequency of Tachycardia Patient Risk Factors Rate of Tachycardia Patient Preference Physician Preference Center philosophy Patient Age
Atrial Arrhythmia and Fontan Type “Classic” Style Fontan Atrio-pulmonary Fontan Lateral Tunnel Fontan/Intra-atrial Conduit Extra-cardiac Conduit Fontan Fenestrated Kutty et al., Heart, 2015
Fontan Cardiac Type Fishberger, et al., Jour. Thor. Card. Surgery, 1997
Classic vs Lateral Tunnel Fontan Atrio-pulmonary Fontan Stamm et al., Journ. Thor. Card. Surgery, 2001
Effect of Fontan Type Balaji et al., Cong. Heart Disease, 2013
Atrio-pulmonary Fontan Effect of Fontan Type Extra-Cardiac Fontan Lateral Tunnel Fontan Atrio-pulmonary Fontan Pundi et al., Cong. Heart Disease, 2016
Collins et al, Amer. Heart Journal, 2000
Access to Tachycardia Substrate Kutty et al., Heart, 2015
Access in Differing Styles of Fontan Frequency of Tachycardia Classic Fontan Lateral Tunnel Extra-Cardiac Ease of Ablation Classic Fontan Lateral Tunnel Extra-Cardiac
Accessing Substrate In Extra-cardiac Fontan Moore et al., Heart Rhythm, 2016 Moore et al., Circulation Arr. Elect., 2015
Risks of Fontan Ablation Correa et al., JAHA, 2013
Risks of Fontan Ablation Correa et al., JAHA, 2013
Trans-catheter Ablation Decision Tools Fontan Type Tachycardia Type Frequency of Tachycardia Patient Risk Factors Rate of Tachycardia Patient Preference Physician Preference Center philosophy Patient Age
Fontan Arrhythmia Mechanism Arrhythmias Number % of All (n=80) % of Ablations (n=59) Macro-reentrant 25 31% 42% Focal Atrial Tachycardia 8 10% 14% AVNRT 13 16% 22% AVRT 4 5% 7% VT 5 6% 8% Twin Node Undefined 21 26% n/a 57 procedures on 52 patients 80 arrhythmias identified Correa et al, Circ Arrhythm Electrophys, 2014
Atrial Fibrillation Takahashi et al, Europace, 2008
Trans-catheter Ablation Decision Tools Fontan Type Tachycardia Type Frequency of Tachycardia Patient Risk Factors Rate of Tachycardia Patient Preference Physician Preference Center philosophy Patient Age
Trans-catheter Ablation Decision Tools Fontan Type Tachycardia Type Frequency of Tachycardia Patient Risk Factors Rate of Tachycardia Patient Preference Physician Preference Center philosophy Patient Age
Risk Factors for SCD in Fontan Walsh E, et al, Heart Rhythm, 2014
Arrhythmia Influence on Fontan Diller et al, European Heart Journal, 2010
Risk of Mortality in Fontan Fontan Type Clinical arrhythmias Symptoms of heart failure Diller et al, Eur. Heart Journal, 2010
Trans-catheter Ablation Decision Tools Fontan Type Tachycardia Type Frequency of Tachycardia Patient Risk Factors Rate of Tachycardia Patient Preference Physician Preference Center philosophy
What is The Goal of Fontan Ablation? Hiroshi Nakagawa et al. Circulation, 2001
Outcomes in Fontan Patients With Atrial Arrhythmias Egbe et al, Amer. Heart Journal., 2016
Outcomes in Fontan Patients With Atrial Arrhythmias Egbe et al, Amer. Heart Journal., 2016
Correa et al., Circulation Arrhythmia Elect., 2015
Fontan Conversion/Arrhythmia Surgery Deal et al., Brit. Med. Journal, 2012
Risk of Atrial Tachycardia Recurrence Egbe et al, American Heart Journal, 2017
Trans-catheter Ablation Recurrent Atrial Arrhythmia Decision Patient Age Fontan Type Frequency of Tachycardia Patient Preference Fontan Patient Atrial Arrhythmia DCCV +/- Meds Recurrent Atrial Arrhythmia Surgical Ablation Decision Patient Age Fontan Type Patient Risk Factors Patient Preference Physician Preference Decision Patient Age Fontan Type Frequency of Tachycardia Patient Preference
Conclusions Fontan patients with SVT are likely to have recurrence of SVT Anti-arrhythmic medications are reasonable but unlikely to keep patients tachycardia free New onset Atrial Tachycardia or increased tachycardia burden is often an early indicator of other issues Catheter ablation plays a major role in management of SVT in Fontan patients and is reasonable as first or second line management We need to clearly define our goals The role of catheter ablation varies based on center and patient preference The role of catheter ablation is likely to change significantly over the next decades with change in Fontan anatomy
Patient 1 20 yo with non-fenestrated extra-cardiac Fontan who recently had their first episode of atrial tachycardia They were cardioverted without issue and are now on Coumadin Currently 3 months from this first episode of tachycardia currently on no anti-arrhythmic medications Question 1 Recommend catheter ablation as a first line treatment strategy Recommend monitoring without ablation or anti-arrythmic medication Recommend starting anti-arrhythmic medication without ablation Other
Patient 2 43 yo with a atrio-pulmonary Fontan with history of multiple cardioversions for atrial tachycardia with recent increase in symptomatology and 3-4 episodes in the past 12 months History previous ablation procedure 4 years prior Currently on Coumadin as well as amiodarone with continued breakthrough episodes of tachycardia Question 2 Recommend catheter ablation with continued anti- arrhythmic mediations Recommend monitoring without ablation or anti-arrythmic medication change Recommend starting a new anti-arrhythmic medication or changing anti-arrhythmic medication without ablation Other
Cincinnati Children's Hospital Medical Center
Sudden Death in Fontan Gallego et al, Amer. Journ. Card., 2012 Diller et al, European Heart Journal, 2010
Is There Disease Specific Risk of SCD? Gallego et al, Amer. Journ. Card., 2012
Sudden Death in Fontan’s Khairy et al., Circulation
Sudden Death in Fontan Pundi et al., Cong. Heart Disease, 2016
The Role of Surgical Ablation Deal et al., Brit. Med. Journal, 2012
Definition of Success in Fontan Ablation
Arrhythmic Influence on Single Fontan Diller et al, European Heart Journal, 2010
Fontan Arrhythmia Mechanism Arrhythmias Number % of All (n=80) % of Ablations (n=59) Macro-reentrant 25 31% 42% Focal Atrial Tachycardia 8 10% 14% AVNRT 13 16% 22% AVRT 4 5% 7% VT 5 6% 8% Twin Node Undefined 21 26% n/a 57 procedures on 52 patients 80 arrhythmias identified Access to pulmonary venous atrium Fenestration - 16 Trans-septal - 17 Retrograde - 2 Correa et al, Circ Arrhythm Electrophys, 2014